Clinical significance of α1-adrenoceptor selectivity in the management of benign prostatic hyperplasia

被引：27

作者：

Pool J.L. ^{[1
]}

Kirby R.S. ^{[2
]}

机构：

[1] Department of Medicine, Baylor College of Medicine, Houston, TX 77030, One Baylor Plaza

[2] St. George's Hospital, London WIG 6DE

来源：

International Urology and Nephrology | 2001年 / 33卷 / 3期

关键词：

Public Health; Adverse Effect; Clinical Significance; Clinical Benefit; Benign Prostatic Hyperplasia;

D O I：

10.1023/A:1019504703485

中图分类号：

学科分类号：

摘要：

Alpha1-adrenoceptor antagonists have been shown to provide effective relief from symptoms of benign prostatic hyperplasia (BPH) with attendant improvements in quality of life. Although the α1A-adrenoceptor subtype predominates over other subtypes of α1 adrenoceptors in the prostate gland, there is no evidence that a subselective α-adrenoceptor antagonist provides a clinical advantage over a selective α1-adrenoceptor antagonist in the treatment of patients with BPH. The pharmacokinetic profiles of α1A-adrenoceptor antagonists and their documented penetration of the blood-brain barrier (CNS adverse effects) preclude a clinical benefit of subselective α-adrenoceptor blockers over selective α1 blockers.

引用

页码：407 / 412

页数：5

共 44 条

[1]

Oesterling J.E., Benign prostatic hyperplasia. Its natural history, epidemiologic characteristics, and surgical treatment, Arch Fam Med, 1, (1992)

[2]

Tammela T., Benign prostatic hyperplasia, Drugs Aging, 10, (1997)

[3]

Bylund B., Eikenberg D., Hiebel J., Et al., International Union of Pharmacology nomenclature of adrenoceptors, Pharmacol Rev, 46, (1994)

[4]

Hieble J.P., Bylund D.B., Clarke D.E., Et al., International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: Consensus update, Pharmacol Rev, 47, (1995)

[5]

Barry M.J., Cockett A.T., Holtgrewe H.L., Et al., Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia, J Urol, 150, (1993)

[6]

Berry S., Coffey D., Wash P., Ewing L., The development of benign prostatic hyperplasia, J Urol, 132, (1984)

[7]

Abrams P., New words for old: Lower urinary tract symptoms for "prostatism, Br Med J, 308, (1994)

[8]

Caine M., The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy, J Urol, 136, (1986)

[9]

Furuya S., Kumamoto Y., Yokoyama E., Et al., Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy, J Urol, 128, (1982)

[10]

Caine M., Raz S., Some clinical implications of adrenergic receptors in the urinary tract, Arch Surg, 110, (1975)

← 1 2 3 4 5 →